High‑risk, high‑reward stocks are not for cautious investors but for those with a big risk appetite. These stocks can offer explosive upside tied to breakthrough science, emerging technologies, or fast-moving market cycles. Today, Upstream Bio (UPB), Neurogene (NGNE), and Powerfleet (AIOT) stand out for their potential to deliver large gains if their strategies play out.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The stocks were identified using the TipRanks Stock Screener tool. All three stocks have a Strong Buy consensus rating from analysts and an upside potential of over 100% in the next 12 months.
1. Upstream Bio (UPB)
Upstream Bio is a clinical-stage biotech developing therapies for severe asthma and inflammatory diseases, a market with a huge unmet need. The company’s lead candidate, UPB‑101, targets the TSLP pathway, a proven approach used by major drugmakers. Early data showed that the drug can meaningfully reduce airway inflammation.
If Upstream Bio’s UPB‑101 delivers solid results in later trials, the stock could see a major boost. At the same time, any trial setback could hit UPB stock hard.
Turning to Wall Street, UPB stock has a Strong Buy consensus rating based on six Buys and one Hold assigned in the last three months. At $43.75, the average Upstream Bio stock price target implies upside potential of 326.41%.
2. Neurogene (NGNE)
Neurogene is developing gene therapies for rare neurological disorders, an area where even small clinical wins can create massive value. Its lead program, NGN‑401, targets Rett syndrome, a severe pediatric condition with limited treatment options. Early data from NGN‑401 have shown promising signs of improving neurological function.
Since gene therapy stocks can swing sharply on even small clinical updates, Neurogene could see meaningful upside if results continue to improve. However, there remains a risk that any manufacturing issues or safety concerns could derail progress.
Wall Street’s consensus rating for NGNE stock is Strong Buy based on seven unanimous Buys. The average analyst price target of $86.50 implies an upside potential of 310.34% from current levels.
3. Powerfleet (AIOT)
Powerfleet is a small-cap telematics and fleet management company using AI and data analytics to help enterprises track vehicles, equipment, and logistics operations. Its platform combines IoT, AI, and supply‑chain technology, giving it exposure to a rapidly modernizing industry.
The company’s recent push into AI‑driven insights, such as predictive maintenance and real‑time asset optimization, could help it win larger customers and boost the stock. The risk is that Powerfleet operates in a competitive market, and scaling its platform requires consistent execution.
On TipRanks, analysts have a Strong Buy consensus rating on AIOT stock based on six Buys assigned in the past three months. Further, the average Powerfleet price target of $10.80 per share implies 242.86% upside potential.
